Salute e Benessere

American Heart Association Late-Breaking Science Presentation Reveals Majority…

From the main stage in front of thousands of cardiologists from around the world, Professor Charalambos Antoniades from the University of Oxford delivered the presentation titled "Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA." Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging (ORFAN) study. ORFAN is the world's largest prospective outcomes…
PR Newswire
13/11/2023

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 13 November 2023– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023.Under…
Nasdaq GlobeNewswire
13/11/2023

Pixium Vision announces the conversion of the safeguard proceedings into…

Pixium Vision announces the conversion of the safeguard proceedings into receivershipParis, France, November 13, 2023 – 8:00 pm (CET ) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, today announces the conversion of the safeguard proceedings ( procédure de sauvegarde ) which has been in place since October 9, 2023 into...
Nasdaq GlobeNewswire
13/11/2023

Rx-360 Releases Two New Publications in Support of the Pharmaceutical Industry…

Jim Fries, CEO of Rx-360 commented, "Being able to watch industry peers work together to develop and launch best practice publications is very humbling. We all know that patient safety is of the utmost importance when it comes to the development and commercialization of pharmaceutical products and these two papers show the commitment of the industry to supply chain integrity." Jim Fries, CEO of Rx-360 commented, "Being able to watch industry peers work together to develop and…
PR Newswire
13/11/2023

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of October 31, 2023(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (November 13, 2023 - 6:30 pm)– As of October 31, 2023, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses,...
Nasdaq GlobeNewswire
13/11/2023

Extraordinary General Meeting's minute

Press release Ecully, November 13, 2023 – 6.00 p.m. Minutes of the General Meeting of November 10, 2023 An Extraordinary General Meeting of Spineway shareholders was held on first notice onFriday, November 10, 2023 at 9:30 a.m.at the company's registered office, 7 allée Moulin Berger in Ecully (69).Taking into account the representation of defaulting shareholders by SELARL TULIER POLGE ALIREZAI, asad hocagent appointed by Order of the President of the Commercial...
Nasdaq GlobeNewswire
13/11/2023

Black Friday: yoose releases ICE shaver - meets all of your desires about…

yoose ICE shaver shows the shaver a new design and compact size, making the entire shaver as same as the size of a palm while maintains the comfortable shaving experience, so that shaving occasions are no longer limited to specific location. The structure design of yoose ICE shaver makes it extremely portable and it weighs only 110 grams, which is about 2/3 of the weight of iPhone 15. yoose ICE shaver meets unpredictable shaving needs whether consumers are traveling/business trip/at office/on a…
PR Newswire
13/11/2023

Artificial Intelligence in Drug Discovery Market Worth $4.9 Billion |…

Browse in-depth TOC on "Artificial Intelligence in Drug Discovery Market" 150 - Tables 50 - Figures 200 - Pages Artificial Intelligence in Drug Discovery Market Scope: "Services segment is expected to grow at the highest rate during the forecast period." Based on offering, the AI in drug discovery market is bifurcated into software and services. In 2022, the services segment is poised to register the highest CAGR throughout the forecast...
PR Newswire
13/11/2023

Data Analytics to Fuel Skin Bioactive Market Growth, Market Valuation to Top US$…

NEWARK, Del., Nov. 13, 2023 /PRNewswire/ -- The skin bioactive market size is poised to cross US$ 1,942.80 million in 2024 and will likely attain a valuation of US$ 3,642.50 million by 2034. The skin bioactive market is projected to grow at a CAGR of 6.5% from 2024 to 2034. NEWARK, Del.,Nov. 13, 2023/PRNewswire/ -- The skin bioactive market size is poised to crossUS$ 1,942.80 millionin 2024 and will likely attain a valuation ofUS$ 3,642.50 millionby 2034. The skin bioactive market...
PR Newswire
13/11/2023

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and…

Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany, Nov.13, 2023(GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma , announced today favorable results from its head-to-head trial with KET01, the Company's proprietary lead asset, versus SPRAVATO ®, the FDA-approved intranasal spray for patients with...
Nasdaq GlobeNewswire
13/11/2023

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and…

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues to be well tolerated with a safety profile consistent with prior clinical trials - - Presented survival outcomes data from the Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab in patients...
Nasdaq GlobeNewswire
13/11/2023

Study confirms powerful effects of Lumenato® on improving skin structure and…

To understand the benefits of Lumenato on skin structure, 59 healthy women between ages 35-55 of varying ethnicities (Caucasian, Latino) and skin types (II, III, IV) were studied. The women had a baseline TEWL of ≥12G/M2/Hr and were split into two groups to receive Lumenato soft gel capsules (10mg total carotenoids) or placebo soft gel capsules (pure glycerin) for 12 weeks, daily. To understand the benefits of Lumenato on skin structure, 59 healthy women between ages 35-55 of varying...
PR Newswire
13/11/2023

Trading in Novo Nordisk shares by board members, executives and associated…

Bagsværd, Denmark, 13 November 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
13/11/2023

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat)…

Medison and Ipsen are part of a multiregional partnership in both Canada and Israel to bring Bylvay, a highly innovative therapy for the treatment of pruritus due to PFIC, offering new hope for patients suffering from this rare disease, and their families. Medison and Ipsen are part of a multiregional partnership in bothCanadaandIsraelto bring Bylvay, a highly innovative therapy for the treatment of pruritus due to PFIC, offering new hope for patients suffering from this rare disease,...
PR Newswire
13/11/2023

FEELM2.0 Receives Awards for the 'Best Innovation in the Vaping Industry' for…

The conference is followed by the UKVIA Industry Recognition Awards selected by the panel of expert judges, with only the Award for the Best Innovation in the Vaping Industry voted by the attendees of the forum. The conference is followed by the UKVIA Industry Recognition Awards selected by the panel of expert judges, with only the Award for the Best Innovation in the Vaping Industry voted by the attendees of the forum. FEELM2.0, the technology solution to deliver more than 1000 puffs in 2mL...
PR Newswire
13/11/2023

SCOTTISH INNOVATION COMPANY LAUNCHES A REVOLUTIONARY NEW FOOT STRENGTHENING…

Most people who wear modern shoes have feet which only operate at 50-60% of their natural strength levels. Correcting this weakness can improve an athlete's performance and help people avoid injury. Astonishingly, a recent study showed that strengthening the foot can reduce the risk of running injuries by more than half. Most people who wear modern shoes have feet whichonly operate at 50-60%of their natural strength levels. Correcting this weakness can improve an athlete's performance and...
PR Newswire
13/11/2023

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended…

Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M). BPaL drastically reduces the time it takes to cure drug-resistant TB, with fewer side effects. Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment. BPaL is the first set treatment regimen recommended to…
PR Newswire
13/11/2023

Mission Therapeutics announces publication in Nature Communications outlining…

Mission Therapeutics is a global leader in discovering and developing innovative therapeutics that promote mitophagy. This quality control process enables the removal of dysfunctional mitochondria, thereby improving cell health and function. Parkinson's Disease is highly associated with mitochondrial dysfunction, making it a key pathophysiological driver. Mission believes that by improving mitophagy, it can reduce the burden of dysfunctional mitochondria and thus slow or prevent the progression…
PR Newswire
13/11/2023

Millar to Acquire Sentron; Redefining MEMS Pressure Sensor Industry

Millar's intent to acquire Sentron represents a transformative step forward for MEMS pressure sensor technology. This merger would amplify Millar's global footprint, enhance product distribution capabilities, and establish Millar as a one-stop-shop for sensor development, from raw components to fully commercialized, sensor-enabled medical devices. This strategic acquisition including the sensor development and fabrication facilities will significantly broaden Millar's capabilities, enabling the…
PR Newswire
13/11/2023

Ultimovacs ASA: New share capital registered

The share capital increase related to the share issue of 9,600 new shares has been registered in the Norwegian Register of Business Enterprises, and the Company's new share capital is NOK 3,440,606.10, divided into 34,406,061 shares, each with a par value of NOK 0.10. For further information, please contact: Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASAEmail: je@radforsk.no Phone: +47 480 96 355 Carlos de Sousa, CEO Email: carlos.desousa@ultimovacs...
Nasdaq GlobeNewswire
13/11/2023

The FHH Forum 2023, which was held yesterday in Geneva, on the theme "Horology…

Then,Ian Goldin, Professor at theUniversity of Oxfordand world expert in futurology, and Virginie Raisson, President of the IPCC Pays-de-la-Loire, captivated the audience with their keynotes on "The World of Tomorrow: Macro Trends and Perspectives". They highlighted the significant impact of exogenous factors on the watch sector. Continuing with these reflections,Stephen Dunbar-Johnson, President, International for theNew York Times, brilliantly moderated a Q&A session...
PR Newswire
13/11/2023

Oxolife Appoints International Fertility Experts to its Scientific Advisory…

- Support plans to advance clinical development of OXO-001, a novel first in class treatment for infertility - Support plans to advance clinical development of OXO-001, a novel first in class treatment for infertility BARCELONA, Spain,Nov. 13, 2023/PRNewswire/ -- Oxolife, the specialist biotech focused on enhancing embryo implantation in women undergoing Assisted Reproductive Technology (ART) fertility treatment, today announces it has appointed globally renowned fertility experts to...
PR Newswire
13/11/2023

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology…

When used pre-operatively, Telix's radiopharmaceutical imaging agents such as TLX591-CDx (Illuccix®) or TLX250-CDx (Zircaix®)[6] potentially enable improved surgical planning to determine the location and extent of disease. Lightpoint's SENSEI®, a radio-guided surgical probe works in conjunction with suitable cancer-seeking radiotracer agents to enable the intra-operative detection of cancer during a surgical intervention to help accurately answer the question, "where is the cancer?"…
PR Newswire
13/11/2023

ViaNautis Bio announces $25 million Series A financing to drive the next…

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines ViaNautis's proprietary drug delivery platform polyNaut ®is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical needSeries A led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors...
Nasdaq GlobeNewswire
13/11/2023
Altri  Comunicati